The Claim
In pediatric patients who have received a renal transplant and are on a calcineurin inhibitor-free immunosuppressive regimen, the pharmacokinetics of sirolimus are not affected by exposure to mycophenolic acid, as demonstrated by the absence of a significant correlation between the area under the concentration-time curve (AUC) values of sirolimus and mycophenolic acid (r² = 0.04).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In kids who got a kidney transplant and are on a certain anti-rejection drug combo, taking more or less of one drug (mycophenolic acid) doesn’t change how the body handles another drug (sirolimus).
See the scientific wording
In pediatric renal transplant recipients on a calcineurin inhibitor-free immunosuppressive regimen, sirolimus pharmacokinetics are not influenced by mycophenolic acid exposure, as evidenced by no significant correlation between their AUC values (r² = 0.04).
What the research says
1 studyThe study looked at kids with kidney transplants taking sirolimus and mycophenolate, and found that one drug didn’t affect how the body processed the other, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.